Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Onconetix, Inc.

Get SEC filing alerts via email and in your feed for Onconetix, Inc.

ONCO

Onconetix, Inc.

About Onconetix, Inc.

Onconetix is a biotech company specializing in the research, development, and commercialization of diagnostic and therapeutic solutions for men's health and oncology. Its core products include Proclarix, a blood test for prostate cancer risk assessment, and ENTADFI, an FDA-approved drug for BPH. The company leverages proprietary biomarkers, regulatory expertise, and third-party manufacturing to address cancer detection, prognosis, and treatment, serving global markets with a focus on innovation and strategic partnerships.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Onconetix, Inc.

1
1
Onconetix, Inc. Onconetix Reports 78.9% Revenue Decline in Q1 2026, Net Loss Improves to $4.2 Million

Via official filing (AI summary) | 22 days ago | 0 comments

2
1
Onconetix, Inc. Onconetix Reports 67.7% Revenue Decline, Focuses on Proclarix Commercialization

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Onconetix, Inc. Onconetix Reports 25.4% Revenue Decline in Q3 2025, Shifts Focus to Proclarix

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Onconetix, Inc. Onconetix Reports 84.9% Revenue Decline and $2.4 Million Net Loss in Latest Quarter

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Onconetix, Inc. Onconetix Reports 85.5% Revenue Decline and $8.5 Million Net Loss in Q1 2025

Via official filing (AI summary) | 12 months ago | 0 comments

6
1
Onconetix, Inc. Onconetix Reports $2.5 Million Revenue Growth Amid $58.7 Million Net Loss in 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Onconetix, Inc. Onconetix Reports Revenue Growth and Reduced Losses in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments

8
1
Onconetix, Inc. Onconetix Reports Significant Financial Challenges, Net Loss, and Restructuring Efforts

Via official filing (AI summary) | almost 2 years ago | 0 comments